Veracyte (NASDAQ:VCYT) Reaches New 52-Week High Following Analyst Upgrade

2 min read | January 30, 2025 10:28 PM PST | By Team Kalkine Media

Veracyte (NASDAQ:VCYT) Reaches New 52-Week High Following Analyst Upgrade

Stock Performance and Expert Ratings

Shares of Veracyte, Inc. (NASDAQ:VCYT) climbed to a new 52-week high during mid-day trading on Thursday. This surge was propelled by an updated price target from Needham & Company LLC, increasing from $44.00 to $51.00. Currently, Veracyte’s shares reached as high as $46.18, closing slightly higher at $46.56 with a trading volume of 42,960 shares. The stock previously closed at $44.44.

Insider Transactions

Recent insider trading activity includes the sale of 1,050 shares by insider John Leite, valued at approximately $45,412.50. This transaction decreased his ownership by 1.40%, leaving him with 73,810 shares. Similarly, CAO Jonathan Wygant sold 956 shares, reducing his position by 2.32%. Overall, insiders sold a total of 24,038 shares worth approximately $1,008,297 over the past 90 days.

Institutional Investor Activity

Institutional investors are significantly adjusting their holdings in Veracyte. Principal Securities Inc. increased its holdings by 34.1%, while Castleview Partners LLC and Values First Advisors Inc. acquired new positions. KBC Group NV and Point72 Asia Singapore Pte. Ltd. also expanded their stakes, reflecting rising interest in the biotechnology company.

Financial Performance and Future Outlook

Veracyte recently announced robust quarterly earnings results, reporting an earnings per share (EPS) of $0.19, surpassing the consensus estimate of $0.03. The company's revenue rose by 28.6% year-over-year, reaching $115.86 million, exceeding expectations. Despite a slight negative net margin, Veracyte maintained a positive return on equity.

About Veracyte

Veracyte, Inc. is a biotechnology company focused on developing diagnostic products aimed at treating thyroid cancer, improving lung cancer screening, and clarifying the diagnosis of idiopathic pulmonary fibrosis. With a comprehensive portfolio that includes Afirma, Percepta, and Envisia, Veracyte continues its efforts in advancing healthcare diagnostics.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.